We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.21B
AUM Growth
-$804M
Cap. Flow
-$184M
Cap. Flow %
-2.96%
Top 10 Hldgs %
40.63%
Holding
166
New
10
Increased
38
Reduced
80
Closed
12

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$32.4M
2
UNH icon
UnitedHealth
UNH
+$23.7M
3
CI icon
Cigna
CI
+$21.4M
4
HUM icon
Humana
HUM
+$20.1M
5
APLS
Apellis Pharmaceuticals
APLS
+$12.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$72.3M
2
MDT icon
Medtronic
MDT
+$64.4M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$33M
4
CRL icon
Charles River Laboratories
CRL
+$17.5M
5
TMO icon
Thermo Fisher Scientific
TMO
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.77%
3 Energy 0.04%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$29.3B
$64M 1.03%
685,733
-75,983
-10% -$8.57M
PACB icon
27
Pacific Biosciences
PACB
$438M
$60.5M 0.97%
7,245,188
-297,641
-4% -$3.4M
PEN icon
28
Penumbra
PEN
$12.5B
$57.4M 0.92%
237,252
+3,032
+1% +$842K
CLDX icon
29
Celldex Therapeutics
CLDX
$2.87B
$52.3M 0.84%
1,900,000
+100,000
+6% +$3.13M
MOH icon
30
Molina Healthcare
MOH
$11.8B
$52M 0.84%
158,438
-5,900
-4% -$1.86M
EXEL icon
31
Exelixis
EXEL
$14.1B
$51.9M 0.84%
2,375,925
-158,075
-6% -$3.31M
ALGN icon
32
Align Technology
ALGN
$12.6B
$51M 0.82%
166,886
-4,254
-2% -$1.47M
SWAV
33
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$50.6M 0.82%
254,279
-16,247
-6% -$3.84M
MDT icon
34
Medtronic
MDT
$106B
$50.3M 0.81%
641,492
-769,000
-55% -$64.4M
IDXX icon
35
Idexx Laboratories
IDXX
$44.8B
$50M 0.81%
114,441
– –
BIO icon
36
Bio-Rad Laboratories Class A
BIO
$8.11B
$48.2M 0.78%
134,330
-203
-0.2% -$78.3K
ACCD
37
DELISTED
Accolade Inc
ACCD
$47.9M 0.77%
4,527,923
+6,864
+0.2% +$90.1K
MGNX icon
38
MacroGenics
MGNX
$291M
$45.7M 0.74%
9,803,313
+193,400
+2% +$963K
VEEV icon
39
Veeva Systems
VEEV
$31.3B
$45.6M 0.73%
224,100
-46,946
-17% -$9.46M
CRL icon
40
Charles River Laboratories
CRL
$10.5B
$44.9M 0.72%
229,342
-85,171
-27% -$17.5M
TNDM icon
41
Tandem Diabetes Care
TNDM
$1.15B
$44.5M 0.72%
2,142,769
+49,835
+2% +$1.37M
AXSM icon
42
Axsome Therapeutics
AXSM
$12B
$44.1M 0.71%
631,487
+57,124
+10% +$4.27M
LLY icon
43
Eli Lilly
LLY
$1.05T
$43.8M 0.71%
81,541
-13,614
-14% -$7.02M
PODD icon
44
Insulet
PODD
$11.3B
$42.2M 0.68%
264,359
-59,235
-18% -$13.3M
ARVN icon
45
Arvinas
ARVN
$527M
$41.7M 0.67%
2,125,200
-1,800
-0.1% -$44.2K
RLAY icon
46
Relay Therapeutics
RLAY
$4.42B
$41.1M 0.66%
4,885,000
+714,200
+17% +$7.68M
CRSP icon
47
CRISPR Therapeutics
CRSP
$4.74B
$40.8M 0.66%
898,400
-900
-0.1% -$46.5K
HCA icon
48
HCA Healthcare
HCA
$82.3B
$38.3M 0.62%
155,643
-4,872
-3% -$1.33M
CI icon
49
Cigna
CI
$74.8B
$35.9M 0.58%
125,502
+75,103
+149% +$21.4M
JAZZ icon
50
Jazz Pharmaceuticals
JAZZ
$15.6B
$34.5M 0.56%
266,226
-22,553
-8% -$3.01M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2023 Portfolio in Review

As of Q3 2023, Bellevue Group held 166 positions worth $6.21B, down 11% from $7.01B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q3 2023 filing shows 10 new, 38 increased, 80 reduced and 12 closed positions. Its largest new stake was Viatris: 176,848 shares worth $1.74M. The largest sale was Inspire Medical Systems, an estimated $72.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q3 2023 buy was Viatris: 176,848 shares worth $1.74M.
  • Bellevue Group added most to Elevance Health in Q3 2023, an estimated $32.4M increase.
  • Bellevue Group's biggest Q3 2023 reduction was Inspire Medical Systems, cutting an estimated $72.3M.
  • Bellevue Group fully exited Baxter International in Q3 2023, selling an estimated $9.72M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.21B portfolio in Q3 2023.
  • Bellevue Group opened 10 new positions and closed 12 in Q3 2023.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $6.21B.

Based on Bellevue Group's 13F filing for Q3 2023, filed 14 Nov 2023.